TaiMed Biologics (4147) - Total Assets
Based on the latest financial reports, TaiMed Biologics (4147) holds total assets worth NT$4.82 Billion TWD (≈ $151.82 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See TaiMed Biologics net assets for net asset value and shareholders' equity analysis.
TaiMed Biologics - Total Assets Trend (2009–2024)
This chart illustrates how TaiMed Biologics's total assets have evolved over time, based on quarterly financial data.
TaiMed Biologics - Asset Composition Analysis
Current Asset Composition (December 2024)
TaiMed Biologics's total assets of NT$4.82 Billion consist of 67.9% current assets and 32.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 11.6% |
| Accounts Receivable | NT$83.06 Million | 1.7% |
| Inventory | NT$998.06 Million | 20.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$539.40 Million | 10.8% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how TaiMed Biologics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TaiMed Biologics market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TaiMed Biologics's current assets represent 67.9% of total assets in 2024, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 11.6% of total assets in 2024, down from 43.8% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 36.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 20.0% of total assets.
TaiMed Biologics Competitors by Total Assets
Key competitors of TaiMed Biologics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
TaiMed Biologics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.84 | 5.66 | 6.02 |
| Quick Ratio | 14.07 | 4.10 | 3.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$3.13 Billion | NT$3.37 Billion | NT$2.32 Billion |
TaiMed Biologics - Advanced Valuation Insights
This section examines the relationship between TaiMed Biologics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.74 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 28.4% |
| Total Assets | NT$5.00 Billion |
| Market Capitalization | $425.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values TaiMed Biologics's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: TaiMed Biologics's assets grew by 28.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TaiMed Biologics (2009–2024)
The table below shows the annual total assets of TaiMed Biologics from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.00 Billion ≈ $157.50 Million |
+28.39% |
| 2023-12-31 | NT$3.89 Billion ≈ $122.68 Million |
-5.05% |
| 2022-12-31 | NT$4.10 Billion ≈ $129.21 Million |
-11.05% |
| 2021-12-31 | NT$4.61 Billion ≈ $145.26 Million |
-11.27% |
| 2020-12-31 | NT$5.20 Billion ≈ $163.71 Million |
+9.84% |
| 2019-12-31 | NT$4.73 Billion ≈ $149.04 Million |
-1.26% |
| 2018-12-31 | NT$4.79 Billion ≈ $150.94 Million |
+6.40% |
| 2017-12-31 | NT$4.50 Billion ≈ $141.87 Million |
-6.22% |
| 2016-12-31 | NT$4.80 Billion ≈ $151.28 Million |
-2.53% |
| 2015-12-31 | NT$4.93 Billion ≈ $155.21 Million |
+161.95% |
| 2014-12-31 | NT$1.88 Billion ≈ $59.25 Million |
+163.14% |
| 2013-12-31 | NT$714.72 Million ≈ $22.52 Million |
+8.38% |
| 2012-12-31 | NT$659.45 Million ≈ $20.78 Million |
-22.82% |
| 2011-12-31 | NT$854.39 Million ≈ $26.92 Million |
-19.25% |
| 2010-12-31 | NT$1.06 Billion ≈ $33.33 Million |
+71.42% |
| 2009-12-31 | NT$617.22 Million ≈ $19.45 Million |
-- |
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more